{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-076460","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.731507+00:00","generated_at":"2026-06-01T02:30:37.641428+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adicet Bio receives FDA clearance for ADI-270 IND in renal cell carcinoma; Phase 1 trial planned for H2 2024","bullets":["ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.","Phase 1 multicenter, open-label trial in relapsed/refractory clear cell RCC to start in H2 2024; preliminary data expected H1 2025.","ADI-270 is an armored allogeneic off-the-shelf CAR T targeting CD70+ cancers designed for high specificity and tumor infiltration.","Trial will evaluate safety, tolerability, pharmacokinetics, overall response rate, duration of response, and disease control rate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-076460","json":"https://secwatch.observer/filing/0000950170-24-076460.json","markdown":"https://secwatch.observer/filing/0000950170-24-076460.md","text":"https://secwatch.observer/filing/0000950170-24-076460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/0000950170-24-076460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024076460/acet-20240624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:30:37.641428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}